ReviewJournal of clinical and experimental hepatology
Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07387393 (Peau o le Vasa), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peau o le Vasa: Accelerating the Currents of Health Advances for Pasifika People
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical and economic impact of incisional negative pressure wound therapy in breast surgery: meta-analysis.The British journal of surgery · 2026Pooled it
- A Cardiovascular Care Pathway Supported by Remote Patient Management in Dutch Primary Care: Cost-Effectiveness, Budget Impact, and Workload Analysis.JMIR mHealth and uHealth · 2026Article
- Contamination Rates and Economic Evaluation of Reusing Medicated, Preservative-Free, Single-Use Eye Drops.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Cost-effectiveness of integrated behavioral health for depression, anxiety, and chronic pain.The American journal of managed care · 2026Article
- Machine learning approaches for predicting differentiated thyroid cancer recurrence using thyroglobulin levels and whole-body scans: a retrospective cohort study.Scientific reports · 2026Article
- Nanomedicine as an opportunity for equity achievements through cost-reduction in public healthcare for head and neck cancer treatment in Brazil.BMC health services research · 2026Article
- Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Balancing Costs and Clinical Outcomes: A Cost-Effectiveness Study of PICC Types Across Chinese Healthcare Settings.Journal of market access & health policy · 2025Article
- Modeling in R: a practical application using a cost-effectiveness analysis.Health economics review · 2025Review
- Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran.Iranian journal of medical sciences · 2025Article
- Impact of gout flare on health-related quality of life: a multi-center cross-sectional study in Thailand.Clinical rheumatology · 2025Article
- Integrating Social Determinants of Health in Machine Learning-Driven Decision Support for Diabetes Case Management: Protocol for a Sequential Mixed Methods Study.JMIR research protocols · 2024Article
- Optimal decision-making in relieving global high temperature-related disease burden by data-driven simulation.Infectious Disease Modelling · 2024Article
- Markov modeling for cost-effectiveness using federated health data network.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Modelling cost-effectiveness of replacement strategies for ambulance services in the Ministry of Health Malaysia.BMC health services research · 2024Article
- Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
- Article
- Cost-Effectiveness of an Intensive Upper Limb Rehabilitation Therapy for Children With Unilateral Cerebral Palsy: An Economic Evaluation of a Randomized Controlled Trial.Journal of health economics and outcomes research · 2024Article
- Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population.Journal of Korean medical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cost-effectiveness analysis (CEA) provides information on how much extra do we need to spend per unit gain in health outcomes with introduction of any new healthcare intervention or treatment as compared to the alternative. This information is crucial to make decision regarding funding any new drug, diagnostic test or determining standard treatment protocol. It becomes even more important to consider this evidence in resource constrained low-income and middle-income country settings. Generating evidence on costs and consequences of a treatment or intervention could be performed in the setting of a randomized controlled trial, which is the perfect platform to evaluate efficacy or effectiveness. However, we argue that randomized controlled trial (RCT) offers an incomplete setting to generate comprehensive data on all costs and consequences for the purpose of a CEA. Hence, it is needed to use a decision model, either in combination with the evidence from RCT or alone. In this article, we demonstrate the application of decision model-based economic evaluation using 2 separate techniques - a decision tree and a Markov model. We argue that application of a decision model allows computation of health benefits in terms of utility-based measure such as a quality-adjusted life year or disability-adjusted life year which is preferred for a CEA, measure distal costs and consequences which are much more downstream to the application of intervention, allows comparison with multiple intervention and comparators, and provides opportunity of making use of evidence from multiple sources rather than a single RCT which may have limited generalizability. This makes the use of such evidence much more acceptable for clinical use and policy relevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.